- Home
- DEO vs RVMD Comparison
DEO vs RVMD Comparison
Compare DEO & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEO | RVMD |
|---|---|---|
| Founded | 1886 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1B | 40.3B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DEO | RVMD |
|---|---|---|
| Price | $93.47 | $196.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 25 |
| Target Price | $106.29 | ★ $257.80 |
| AVG Volume (30 Days) | 853.6K | ★ 2.0M |
| Earning Date | 08-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.87 | $558.43 |
| P/E Ratio | $90.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.45 | $52.48 |
| 52 Week High | $102.17 | $224.31 |
Technical Indicators
Market Signals| Indicator | DEO | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 37.37 |
| Support Level | $90.36 | $178.19 |
| Resistance Level | $97.06 | $194.19 |
| Average True Range (ATR) | 1.22 | 8.98 |
| MACD | 1.14 | -1.81 |
| Stochastic Oscillator | 83.02 | 19.53 |
Price Performance
Historical ComparisonAbout DEO Diageo plc
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.